Výsledky vyhledávání - "Einarson, TR"

Akademický článek

Patient preferences in severe COPD and asthma: a comprehensive literature review

Autor: Bereza BG, Troelsgaard Nielsen A, Valgardsson S, Hemels MEH, Einarson TR

Publikováno v: International Journal of COPD, Vol 2015, Iss Issue 1, Pp 739-744 (2015)

Basil G Bereza,1 Anders Troelsgaard Nielsen,2 Sverrir Valgardsson,3 Michiel EH Hemels,2 Thomas R Einarson11Leslie Dan Faculty of Pharmacy, University of Toronto, ON, Canada; 2Janssen A/S, Birkerød, Denmark; 3Janssen-Cilag A/S, Oslo, NorwayBackground

Externí odkaz: https://doaj.org/article/e4f143145bda4fa0bcc180d9920380bd

Zobrazit plný text záznamu

Akademický článek

Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective

Autor: Machado M, Einarson TR

Publikováno v: Breast Cancer: Targets and Therapy, Vol 2012, Iss default, Pp 173-182 (2012)

Marcio Machado,1 Thomas R Einarson21GlaxoSmithKline Brasil Ltd, Rio de Janeiro, Brazil; 2Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, CanadaObjective: To evaluate, from the perspective of the Brazilian public health care system, th

Externí odkaz: https://doaj.org/article/26edf50c4db44f8d930212a0cd253eea

Zobrazit plný text záznamu

New Prediction Methods of Indicators and Costs Capable of Increasing the Efficiency of Pharmacoeconomic Studies for Health Decision Analysis

Autor: Cazarim Ms, Einarson Tr

Publikováno v: Pharmaceutica Analytica Acta.

Like most of the resources we have in the world, health-care resources are also scarce. Thus, pharmacoeconomics is very important to aid health systems into this process. It is noteworthy that new methods are being created to improve pharmacoeconomic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::46c900dc751d6ae3d9b1f818bead5c28
https://doi.org/10.4172/2153-2435.1000556

Zobrazit plný text záznamu

A multinational pharmacoeconomic analysis of oral therapies for onychomycosis

Autor: Arikian, SR, Einarson, TR, Kobeltnguyen, G, Schubert, F, Allen, R, Baran, R, Bergman, W, Bitetto, L, Blattstein, JS, Breda, M, Clement, W, De Cuyper, C, Difonzo, E, Van Doorstaer, E, Doyle, JJ, Effendy, Isaak, Eichmann, A, Feuilhade, M, Figueiredo, A, Flori, YA, Germaine, GERMAINE, Camarasa, JMG, Ginter, G, Gisbert, R, Goodfield, M, Groeneweg, DA, Gunn, D, Hannuksela, M, Havu, V, Knappe, E, Koussidou- Eremonti, T, Lateur, N, Lee, RE, Lucioni, C, Mathioudaki, E, Mikultis, R, Nolting, S, Panagiotidou, D, Pekurinen, M, Pereira, J, Rey, JP, Pietrini, P, Soares, AP, Pirard, C, Roberts, DT, Rovira, J, Rufli, T, Rutten, F, Sommer, JH, Spangler, E, Stary, A, Stavrianeas, N, Stavropoulos, P, Stubb, S, Taddio, A, Topolewski, K, Tosti, A, Yfantopoulos, J, Vagena, A, Van Hecke, E, Vareltzidis, A, Zalinski, J

Publikováno v: British Journal of Dermatology. 130:35-44

Due to increased interest in economic evaluation and the rapid international spread of new healthcare technologies across borders, there is a need to interpret economic evaluations on a worldwide basis. We conducted a multinational cost-effectiveness

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a064b66f1a9a5b0b2b5dc723ae425cd
https://doi.org/10.1111/j.1365-2133.1994.tb06093.x

Zobrazit plný text záznamu